C4 Therapeutics Ownership | Who Owns C4 Therapeutics?
C4 Therapeutics Ownership Summary
C4 Therapeutics is owned by 77.02% institutional investors, 9.75% insiders, and 13.23% retail investors. Wasatch advisors lp is the largest institutional shareholder, holding 10.46% of CCCC shares. Wasatch Ultra Growth is the top mutual fund, with 7.25% of its assets in C4 Therapeutics shares.
CCCC Ownership Benchmark
| Type | Name | % Inst | % Insiders | % Retail |
|---|---|---|---|---|
| Stock | C4 Therapeutics | 77.02% | 9.75% | 13.23% |
| Sector | Healthcare Stocks | 487.91% | 11.08% | -398.99% |
| Industry | Biotech Stocks | 307.10% | 11.11% | -218.21% |
Institutional Shareholders
Top Institutional Shareholders by Total Shares
| Holder | Shares | % Holding | Value |
|---|---|---|---|
| Wasatch advisors lp | 7.42M | 10.46% | $10.62M |
| Lynx1 capital management lp | 7.10M | 10.23% | $11.36M |
| Soleus capital management | 6.98M | 9.83% | $9.98M |
| Orbimed advisors | 6.83M | 9.62% | $9.77M |
| Blackrock | 4.55M | 6.61% | $21.03M |
| Vanguard group | 3.35M | 4.81% | $12.05M |
| Blackrock funding, inc. /de | 1.83M | 2.58% | $2.61M |
| Bank of america corp /de/ | 1.77M | 2.57% | $8.17M |
| Geode capital management | 1.38M | 1.98% | $4.97M |
| State street | 1.22M | 1.76% | $4.40M |
Top Institutional Shareholders by % of Total Assets
| Holder | Shares | % Assets | Value |
|---|---|---|---|
| Lynx1 capital management lp | 7.10M | 4.07% | $11.36M |
| Soleus capital management | 6.98M | 0.66% | $9.98M |
| Orbimed advisors | 6.83M | 0.24% | $9.77M |
| Bain capital life sciences investors | 1.11M | 0.20% | $1.59M |
| Vienna powszechne towarzystwo emerytalne s.a. vienna insurance group | 85.00K | 0.08% | $121.55K |
| Tang capital management | 900.00K | 0.07% | $1.29M |
| Wasatch advisors lp | 7.42M | 0.06% | $10.62M |
| Intrepid family office | 40.00K | 0.05% | $57.20K |
| Atom investors lp | 190.18K | 0.02% | $271.96K |
| Hennion & walsh asset management | 205.03K | 0.02% | $455.17K |
Top Buyers
| Holder | Shares | % Assets | Change |
|---|---|---|---|
| Blackrock | 4.55M | 0.00% | 3.65M |
| Wasatch advisors lp | 7.42M | 0.06% | 700.25K |
| Morgan stanley | 1.14M | 0.00% | 623.75K |
| Ubs group | 757.85K | 0.00% | 423.77K |
| Lynx1 capital management lp | 7.10M | 4.07% | 245.39K |
Top Sellers
| Holder | Shares | % Assets | Change |
|---|---|---|---|
| Ra capital management | - | - | -4.88M |
| Blackrock funding, inc. /de | 1.83M | - | -3.46M |
| Commodore capital lp | - | - | -3.41M |
| Samlyn capital | - | - | -3.02M |
| State street | 1.22M | 0.00% | -1.58M |
New Positions
| Holder | Shares | % Assets | Change | Value |
|---|---|---|---|---|
| Susquehanna portfolio strategies | 126.90K | 0.00% | 126.90K | $181.47K |
| Crestwood advisors group | 29.00K | 0.00% | 29.00K | $41.47K |
| Lpl financial | 22.10K | 0.00% | 22.10K | $102.10K |
| Dynamic technology lab private | 21.48K | 0.00% | 21.48K | $31.00K |
| Ewa | 16.64K | 0.01% | 16.64K | $23.80K |
Sold Out
| Holder | Change |
|---|---|
| Gradient investments | -25.00 |
| True wealth design | -31.00 |
| Coldstream capital management | -52.00 |
| Capital performance advisors llp | -54.00 |
| Rothschild investment | -70.00 |
Institutional Ownership Trends
| Date | Holdings | Change % | Shares | Change % | Ownership | Change % | Increased Position | Change % | Decreased Position | Change % |
|---|---|---|---|---|---|---|---|---|---|---|
| Jun 30, 2025 | 100 | -13.04% | 54,689,267 | -14.68% | 77 | 0.90% | 55 | -19.12% | 33 | 17.86% |
| Mar 31, 2025 | 6 | -95.20% | 21,025,800 | -67.35% | 30 | 0.35% | 4 | -93.85% | 1 | -96.97% |
| Dec 31, 2024 | 122 | -5.43% | 64,367,933 | 0.29% | 92 | 1.09% | 63 | -7.35% | 33 | 3.13% |
| Sep 30, 2024 | 126 | 5.88% | 64,029,825 | 5.20% | 91 | 1.18% | 67 | 1.52% | 33 | -2.94% |
| Jun 30, 2024 | 119 | 7.21% | 60,865,031 | 4.84% | 88 | 1.23% | 66 | -1.49% | 34 | 25.93% |
Top Mutual Funds Shareholders
| Holder | Shares | % Holding | Change |
|---|---|---|---|
| Wasatch Ultra Growth | 5.15M | 7.25% | 593.72K |
| Vanguard US Total Market Shares ETF | 2.14M | 3.01% | - |
| Vanguard Total Stock Mkt Idx Inv | 2.03M | 2.85% | -44.74K |
| Biotech Growth Ord | 1.75M | 2.46% | - |
| SPDR® S&P Biotech ETF | 1.57M | 2.22% | 22.34K |
| iShares Russell 2000 ETF | 1.53M | 2.16% | - |
| Wasatch Micro Cap | 758.27K | 1.07% | -483.88K |
| Fidelity Small Cap Index | 623.59K | 0.88% | -8.75K |
| Vanguard Institutional Extnd Mkt Idx Tr | 608.71K | 0.86% | -231.45K |
| iShares Russell 2000 Value ETF | 560.98K | 0.79% | - |
Recent Insider Transactions
| Date | Name | Role | Activity | Value |
|---|---|---|---|---|
| Feb 18, 2025 | Boyle Scott N | Chief Business Officer | Sell | $2.11K |
| Feb 14, 2025 | Boyle Scott N | Chief Business Officer | Sell | $1.54K |
| Feb 08, 2023 | Koppikar Utpal | - | Buy | $31.74K |
| Apr 12, 2022 | Hirsch Andrew | President & CEO | Buy | $84.00K |
| Jan 04, 2022 | Crystal Adam | Chief Medical Officer | Sell | $440.55K |
Insider Transactions Trends
| Date | Buy | Sell |
|---|---|---|
| 2025 Q4 | - | - |
| 2025 Q3 | - | - |
| 2025 Q2 | - | - |
| 2025 Q1 | - | 2 |
| 2024 Q4 | - | - |
CCCC Ownership FAQ
Try Tickergate Pro Free
Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)
Customize your own personal stocks lists, views and charts
Choose from hundreds of fields, up to 15 years of history
Conduct deep comparison analysis
Discover trending investment themes
Find your next best investment
Research stocks using tools